AR027362A1 - Celula tumoral haptenizada de baja dosis e inmunoterapia de extracto celular tumoral - Google Patents
Celula tumoral haptenizada de baja dosis e inmunoterapia de extracto celular tumoralInfo
- Publication number
- AR027362A1 AR027362A1 ARP010100510A ARP010100510A AR027362A1 AR 027362 A1 AR027362 A1 AR 027362A1 AR P010100510 A ARP010100510 A AR P010100510A AR P010100510 A ARP010100510 A AR P010100510A AR 027362 A1 AR027362 A1 AR 027362A1
- Authority
- AR
- Argentina
- Prior art keywords
- haptenized
- tumor cell
- cells
- patients
- vaccines
- Prior art date
Links
- 210000004881 tumor cell Anatomy 0.000 title abstract 4
- 239000000284 extract Substances 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 201000001441 melanoma Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- -1 dinitrophenyl group Chemical group 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se relaciona con composiciones que comprenden células tumorales haptenizadas y extractos de las mismas, métodos para preparar lascomposiciones, vacunas que comprenden a tales células de tumor haptenizadas, y métodos para el tratamiento de l cáncer con tales vacunas. En una realizacionespecifica, las células de melanoma son haptenizadas con un grupo dinitrofenilo, y utilizadas para el tratamiento de pacientes con melanoma que tienenenfermedad metastásica. Preferentemente, se le suminis tra a los pacientes una primer dosis de vacuna que contiene células haptenizadas como imprimacion delsistema inmune. Subsecuentemente, los pacientes son inyectados con un compuesto inmunomodulador tal como ciclofosfamida. En una realizacion preferida en unperiodo de tiempo apropiado después de la dosis de vacuna de imprimacion es administrada dosis de vacunas adicionales que contienen una mezcla de célulashaptenizadas y un adyuvante. El plan de tratamiento descrito es más efectivo para estimular respuestas inmunes anti-tumor favorables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18025800P | 2000-02-04 | 2000-02-04 | |
| US25950101P | 2001-01-03 | 2001-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR027362A1 true AR027362A1 (es) | 2003-03-26 |
Family
ID=26876131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100510A AR027362A1 (es) | 2000-02-04 | 2001-02-02 | Celula tumoral haptenizada de baja dosis e inmunoterapia de extracto celular tumoral |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7297330B2 (es) |
| EP (1) | EP1253940A2 (es) |
| AR (1) | AR027362A1 (es) |
| AU (1) | AU785031B2 (es) |
| CA (1) | CA2399603A1 (es) |
| WO (1) | WO2001056601A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2302337T3 (es) * | 1995-06-07 | 2008-07-01 | Thomas Jefferson University | Extracto de celulas tumorales modificadas con hapteno y procedimientos para tratar cancer. |
| US20090087450A1 (en) * | 2000-01-11 | 2009-04-02 | Greenville Hospital System | Combination therapy of hybrid cells with BCG injection for treating Cancer Patients |
| US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US20040076646A1 (en) * | 2001-07-18 | 2004-04-22 | Caplan Michael J. | Haptenizing cancer cell components |
| US20030165518A1 (en) * | 2002-02-01 | 2003-09-04 | Thomas Jefferson University | Mixed haptenized tumor cells and extracts and methods of treating or screening for cancer |
| JP2005528901A (ja) * | 2002-06-10 | 2005-09-29 | アバクス・テクノロジーズ・インコーポレーテッド | ハプテン化腫瘍細胞の凍結保存 |
| GB0221574D0 (en) * | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| WO2006076508A2 (en) * | 2005-01-14 | 2006-07-20 | Avax Technologies, Inc. | Method for producing a vaccine for the treatment of cancer |
| US9540427B2 (en) * | 2007-05-30 | 2017-01-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Peptide-based stat inhibitor |
| CN116092631A (zh) * | 2023-01-17 | 2023-05-09 | 湖南安泰康成生物科技有限公司 | 铁死亡诱导剂与电场联用的肿瘤治疗系统 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5290551A (en) | 1990-05-08 | 1994-03-01 | Thomas Jefferson University | Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten |
| US20020004052A1 (en) * | 1990-05-08 | 2002-01-10 | David Berd | Composition comprising a tumor cell extract and method of using the composition |
| NZ238731A (en) * | 1990-06-27 | 1996-02-27 | Univ Emory | Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide |
| DE4143467C2 (de) | 1991-05-17 | 1995-02-09 | Max Planck Gesellschaft | Peptidmotiv und dessen Verwendung |
| DE69332485T2 (de) | 1992-08-11 | 2003-11-13 | Harvard College | Immunmodulierende peptide |
| US5487982A (en) | 1993-05-21 | 1996-01-30 | University Of Pittsburgh | Method of obtaining immunogenic peptides from cells expressing temperature-sensitive mutants of major histocompatibility complex molecules |
| ES2302337T3 (es) | 1995-06-07 | 2008-07-01 | Thomas Jefferson University | Extracto de celulas tumorales modificadas con hapteno y procedimientos para tratar cancer. |
| IL125747A0 (en) | 1996-10-04 | 1999-04-11 | Univ Jefferson | T cells mediating an immune response and methods of use |
| US6017540A (en) * | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| EP1119365A4 (en) * | 1997-07-24 | 2003-08-13 | Univ Jefferson | COMPOSITIONS AND METHODS FOR USING TUMOR CELLS |
| KR20010041018A (ko) | 1998-02-17 | 2001-05-15 | 토마스 제퍼슨 유니버시티 | 합텐으로 변형된 종양 세포막, 및 합텐으로 변형된 종양세포막의 제조방법 및 용도 |
| WO1999052546A2 (en) | 1998-04-09 | 1999-10-21 | Thomas Jefferson University | A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient |
| IL139442A0 (en) | 1998-05-04 | 2001-11-25 | Univ Jefferson | Composition comprising tumor cells and extracts and method of using thereof |
| US6248585B1 (en) * | 1998-11-19 | 2001-06-19 | Thomas Jefferson University | Compositions for preserving haptenized tumor cells for use in vaccines |
| AU1744600A (en) | 1998-11-24 | 2000-06-13 | Thomas Jefferson University | Detection of t cell stimulating tumor antigens |
| WO2000038710A2 (en) | 1998-12-30 | 2000-07-06 | Thomas Jefferson University | Dual hapten modified tumor cells and tumor polypeptides and methods of treating cancer |
| CA2367922A1 (en) * | 1999-03-16 | 2000-10-05 | Thomas Jefferson University | Hapten-conjugated mammalian cells and methods of making and using thereof |
| US20010046502A1 (en) * | 2000-02-04 | 2001-11-29 | The Board Of Trustees Of The University Of Illinois | Animal model for testing immunotherapies of spontaneous metastatic disease |
| US20030165518A1 (en) * | 2002-02-01 | 2003-09-04 | Thomas Jefferson University | Mixed haptenized tumor cells and extracts and methods of treating or screening for cancer |
| WO2003063801A2 (en) * | 2002-02-01 | 2003-08-07 | Thomas Jefferson University | Treatment of tumor cells for use in immunotherapy of cancer |
| JP2005528901A (ja) * | 2002-06-10 | 2005-09-29 | アバクス・テクノロジーズ・インコーポレーテッド | ハプテン化腫瘍細胞の凍結保存 |
| WO2006076508A2 (en) * | 2005-01-14 | 2006-07-20 | Avax Technologies, Inc. | Method for producing a vaccine for the treatment of cancer |
-
2001
- 2001-02-01 US US09/776,250 patent/US7297330B2/en not_active Expired - Lifetime
- 2001-02-02 EP EP01905369A patent/EP1253940A2/en not_active Withdrawn
- 2001-02-02 WO PCT/US2001/003448 patent/WO2001056601A2/en active IP Right Grant
- 2001-02-02 CA CA002399603A patent/CA2399603A1/en not_active Abandoned
- 2001-02-02 AU AU33257/01A patent/AU785031B2/en not_active Ceased
- 2001-02-02 AR ARP010100510A patent/AR027362A1/es unknown
-
2004
- 2004-12-17 US US11/015,769 patent/US20050232951A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2399603A1 (en) | 2001-08-09 |
| AU3325701A (en) | 2001-08-14 |
| EP1253940A2 (en) | 2002-11-06 |
| US20050232951A1 (en) | 2005-10-20 |
| US7297330B2 (en) | 2007-11-20 |
| WO2001056601A3 (en) | 2002-04-18 |
| WO2001056601A2 (en) | 2001-08-09 |
| US20020009469A1 (en) | 2002-01-24 |
| WO2001056601A9 (en) | 2002-10-31 |
| AU785031B2 (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR004445A1 (es) | Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada | |
| AR027362A1 (es) | Celula tumoral haptenizada de baja dosis e inmunoterapia de extracto celular tumoral | |
| AR068984A1 (es) | Proceso para la obtencion de celulas presentadoras de antigenos activados, utiles en las terapias contra el cancer y enfermedades relacionadas del sistema inmunologico | |
| RU2010115220A (ru) | Применение mva (модифицированный вирус коровьей оспы анкара) для лечения рака простаты | |
| BRPI0010612B8 (pt) | vacinas | |
| RU2018105666A (ru) | Способы лечения метастатического рака поджелудочной железы с помощью комбинированной терапии, включающей применение иринотекана и оксалиплатина | |
| EP0719150A4 (en) | CELL VACCINE AND METHODS OF USE IN THE TREATMENT OF SOLID MALIGNANT TUMORS | |
| MX2019010725A (es) | Metodos y composiciones para tratar canceres usando antisentido. | |
| Gregoire et al. | Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia | |
| EP1723963A3 (en) | Hapten-conjugated tumour cells | |
| CN105853963A (zh) | 一种预防和治疗脱发的中药配方 | |
| Gray et al. | Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase‐treated autologous tumour cells in large bowel cancer | |
| IL189615A0 (en) | Melanoma vaccine and methods of making and using same | |
| MX2021005169A (es) | Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido. | |
| RU2678083C2 (ru) | Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10 | |
| CN102153658A (zh) | 肿瘤抗原、dc肿瘤疫苗及其制备方法 | |
| CN114366810A (zh) | 一种可高效诱导体液和细胞免疫的天然微生物和植物来源复合双佐剂及其制备方法和应用 | |
| AR023925A1 (es) | Extracto de celulas tumorales modificadas por haptenizacion dual y metodos de tratamiento o proteccion para cancer | |
| MX2021005168A (es) | Metodos y composiciones para el tratamiento de cancer de mama usando antisentido. | |
| ES2399218T3 (es) | Saponinas inmunoestimulantes para usar en terapia de destrucción tumoral in situ | |
| AR118282A1 (es) | Formulaciones inmunogénicas para el tratamiento del cáncer | |
| MX2021011760A (es) | Metodos para el tratamiento de canceres usando antisentido. | |
| WO2004002412A3 (en) | A method and composition to elicit an effective autologous antitumoral immune response in a patient | |
| Atzpodien et al. | Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients | |
| Adler | DNCB for local control of malignant melanoma: don't forget a winning horse! |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |